The quantity of data that is currently produced in everyday life and practically in every sector, is...
Associate Professor in Endocrinology MED/13
Member of Presidio Qualità,
Member of the Board for the PhD program in Molecular and Experimental Medicine,
Head of Residency Program in Endocrinology and Metabolism
Coordinator System Disease 3, School of Medicine, Humanitas University
Andrea Lania was born in Milan in 1965. After the degree in Medicine and the postgraduate degree in Endocrinology, Prof. Lania received the PhD degree in Endocrinological and Metabolic Sciences at the University of Milan. From 2005 to 2015 he was Assistant Professor of Endocrinology at the BIOMETRA Department at the University of Milan.
Since 2015 he is Associate professor of Endocrinology at the Biomedical Sciences Department at Humanitas University in Rozzano (Milan). Actually he is the Director of the Residency Program in Endocrinology at Humanitas University.
Since 2010 Professor Lania is the Director of the Endocrinolgy, Diabetology and Andrology Unit and the Laboratory of Cellular and Molecular Endocrinology at IRCCS Istituto Clinico Humanitas. He coordinates (with Dr. Lasio) the Pituitary Unit as well as (with Prof. Zerbi) the Neuroendocrine multidisciplinary tumor board certified as Center of Excellence by the European NeuroEndocrine Tumors Society (ENETS). Finally, Prof. Lania is Humanitas Research Hospital Representative at ERN EURACAN (European Reference Network on adult cancer – solid tumors).
Prof. Lania is author of 152 articles (h-index 32) and he is member of the Editorial Board of several International Journals
Scientific and Research Interests
The research activity of Prof. Lania is mainly focused on the pathogenesis of endocrine tumors (mainly pituitary and neuroendocrine tumors) and the mechanisms involved in determining the sensitivity of these tumors to medical treatment. In particular, he contributed to clarify the impact of the cAMP pathway in the tumorigenesis processes at the pituitary level and to study the intracellular mechanisms elicited by somatostatin receptors in determining their antiproliferative and antisercretory effects. Recently, he has been involved in studies evaluating the possible role of cytoskeleton proteins in determining either the clinical presentation or the response to medical treatment in endocrine tumors.
- Tresoldi AS, Carosi G, Betella N, Del Sindaco G, Indirli R, Ferrante E, Sala E, Giavoli C, Morenghi E, Locatelli M, Milani D, Mazziotti G, Spada A, Arosio M, Mantovani G, Lania AGA. Clinically non-functioning pituitary incidentalomas: characteristics and natural history. Neuroendocrinology. 2019 Sep 13. doi: 10.1159/000503256. [Epub ahead of print] PubMed PMID: 31525736.
- Vitali E, Boemi I, Rosso L, Cambiaghi V, Novellis P, Mantovani G, Spada A, Alloisio M, Veronesi G, Ferrero S, Lania AG. FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression. Oncotarget. 2017 Aug 24;8(44):77330-77340. doi: 10.18632/oncotarget.20473. eCollection 2017 Sep 29. PubMed PMID: 29100390; PubMed Central PMCID: PMC5652783.
- Cambiaghi V, Vitali E, Morone D, Peverelli E, Spada A, Mantovani G, Lania AG. Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. Endocrine. 2017 Apr;56(1):146-157. doi: 10.1007/s12020-016-1026-2. Epub 2016 Jul 12. PubMed PMID: 27406390.
- Beck-Peccoz P, Rodari G, Giavoli C, Lania A. Central hypothyroidism – a neglected thyroid disorder. Nat Rev Endocrinol. 2017 Oct;13(10):588-598. doi: 10.1038/nrendo.2017.47. Epub 2017 May 26. Review. PubMed PMID: 28549061.
- Vitali E, Cambiaghi V, Zerbi A, Carnaghi C, Colombo P, Peverelli E, Spada A, Mantovani G, Lania AG. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016 Mar;23(3):181-90. doi: 10.1530/ERC-15-0358. Epub 2016 Jan 5. PubMed PMID: 26733502